Clearside Biomedical, Inc. Logo

Clearside Biomedical, Inc.

Developing therapies for back-of-the-eye diseases via proprietary suprachoroidal delivery.

CLSD | NDAQ

Overview

Corporate Details

ISIN(s):
N/A
LEI:
Country:
United States of America
Address:
900 NORTH POINT PARKWAY, 30005 ALPHARETTA
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Clearside Biomedical, Inc. is a biopharmaceutical company focused on developing and delivering therapies for serious back-of-the-eye diseases. The company is a leader in suprachoroidal delivery, utilizing its proprietary, patented SCS Microinjector® to precisely administer treatments to the site of disease. Its key commercial product is XIPERE®, the first and only FDA-approved therapy delivered via the suprachoroidal space for the treatment of macular edema associated with uveitis. Clearside's clinical pipeline is led by CLS-AX, a tyrosine kinase inhibitor (TKI) in a Phase 3 program for wet age-related macular degeneration (Wet AMD). The company leverages its validated technology, extensive clinical experience, and strategic collaborations to advance treatments for various retinal conditions.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
No filings match the current criteria.

Automate Your Workflow. Get a real-time feed of all Clearside Biomedical, Inc. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Clearside Biomedical, Inc.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Clearside Biomedical, Inc. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Company Country Ticker View
AGIOS PHARMACEUTICALS, INC. Logo
Pioneering cellular metabolism therapies for rare, genetically defined diseases like anemias.
United States of America AGIO
AIM ImmunoTech Inc. Logo
Develops immuno-therapeutics for cancers, immune disorders, and viral diseases.
United States of America AIM
AKANDA CORP. Logo
Cultivates and distributes pharma-quality medical cannabis for patients in legal markets worldwide.
United States of America AKAN
Akari Therapeutics Plc Logo
A clinical-stage oncology company developing next-gen ADCs for targeted cancer therapy.
United States of America AKTX
Akebia Therapeutics, Inc. Logo
Developing and commercializing novel, FDA-approved therapeutics for kidney disease.
United States of America AKBA
Akero Therapeutics, Inc. Logo
A clinical-stage biotech developing therapies for serious metabolic diseases like MASH.
United States of America AKRO
Alaunos Therapeutics, Inc. Logo
Developing TCR-T cell therapies to treat solid tumors by targeting specific cancer mutations.
United States of America TCRT
Aldeyra Therapeutics, Inc. Logo
Biotech developing therapies for ocular and systemic immune-mediated inflammation.
United States of America ALDX
Alector, Inc. Logo
Pioneers immuno-neurology therapies for neurodegenerative diseases like Alzheimer's.
United States of America ALEC
Aligos Therapeutics, Inc. Logo
Clinical-stage biopharma developing novel oral therapies for liver and viral diseases.
United States of America ALGS

Talk to a Data Expert

Have a question? We'll get back to you promptly.